Abstract
Solid clinical evidence supports the effectiveness and safety of multiple drugs in treating diabetes, dyslipidemia, and hypertension, and numerous fixed-dose combination products (FDCs) containing such drugs have been developed for patients with more severe forms of these diseases. We sought to evaluate the extent to which utilization of treatment combinations for these conditions corresponded to the availability of FDCs. Using claims data from a large national commercial insurer, we identified 2 cohorts of patients: those who filled multiple single-agent drugs to treat diabetes, dyslipidemia, and hypertension in 2012, and those who used FDCs containing these products during the same period. We determined the fill rate of single-agent pairs and FDCs, availability of FDCs for the most frequently filled single-agent and drug class pairs, and the number of conditions treated by frequently filled single-agent pairs and FDCs. During our study period, 848,082 patients filled prescriptions for 3,248 unique single-agent pairs (mean 4.7 per patient, standard deviation [SD] 5.0); and 568,923 patients received prescriptions for 43 unique FDCs (mean 1.1 per patient, SD 0.3). Three (15%) of the 20 most frequently filled single-agent pairs w...Continue Reading
References
Jun 28, 2003·BMJ : British Medical Journal·N J Wald, M R Law
Aug 16, 2005·Pharmacoepidemiology and Drug Safety
Nov 18, 2005·The American Journal of Cardiology·David G Orloff
Nov 23, 2006·Nature Reviews. Drug Discovery·Simon Frantz
Feb 22, 2008·Journal of General Internal Medicine·Feng PanA Mark Fendrick
Oct 29, 2008·Pharmacoepidemiology and Drug Safety·Niteesh K ChoudhryWilliam H Shrank
Apr 3, 2009·Lancet·UNKNOWN Indian Polycap Study (TIPS)N Thomas
Aug 12, 2009·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food and Drug Administration
Dec 23, 2009·Hypertension·Ajay K GuptaNeil R Poulter
Mar 31, 2010·Circulation·Steven Baroletti, Heather Dell'Orfano
May 13, 2010·JAMA : the Journal of the American Medical Association·Harindra C WijeysunderaSimon Capewell
Sep 3, 2013·Diabetes Research and Clinical Practice·Jun-Sing WangUNKNOWN acarbose/metformin fixed-dose combination study investigators
Sep 5, 2013·JAMA : the Journal of the American Medical Association·Simon ThomUNKNOWN UMPIRE Collaborative Group
Dec 20, 2013·JAMA : the Journal of the American Medical Association·Paul A JamesEduardo Ortiz
Feb 5, 2014·Health Affairs·Niteesh K ChoudhryPrabhat Jha
Citations
Feb 10, 2016·Pharmaceutical Research·Manoela K RiekesGuy Van den Mooter
Feb 27, 2016·The Journal of Clinical Hypertension·Kalyani B Sonawane DeshmukhRichard A Hansen
Nov 5, 2016·Expert Opinion on Emerging Drugs·Avivit CahnItamar Raz
Apr 8, 2017·PloS One·Bo WangAaron S Kesselheim
Apr 26, 2018·Journal of Managed Care & Specialty Pharmacy·Julie C LauffenburgerNiteesh K Choudhry
Apr 19, 2020·American Journal of Hypertension·Matthew R Weir
Jun 25, 2020·Clinical Pharmacology in Drug Development·Ki Young HuhSeungHwan Lee
Jan 5, 2017·Journal of General Internal Medicine·Julie C LauffenburgerMichael A Fischer
Aug 25, 2018·JAMA : the Journal of the American Medical Association·Chana A SacksJerry Avorn
Jan 30, 2019·Therapeutic Innovation & Regulatory Science·Chikara KikuchiTakao Aoyama
Oct 15, 2020·Current Hypertension Reports·Jaejin AnCynthia A Jackevicius
Aug 10, 2020·American Heart Journal·Julie C LauffenburgerNiteesh K Choudhry
Mar 27, 2021·Scientific Reports·Julien CastioniPedro Marques-Vidal